Cognition Therapeutics (NASDAQ:CGTX) Rating Increased to Strong-Buy at Brookline Cap M

Brookline Cap M upgraded shares of Cognition Therapeutics (NASDAQ:CGTX) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports. Brookline Cap M also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

A number of other equities research analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 4th. B. Riley Financial reaffirmed a “buy” rating and issued a $3.00 price objective (up previously from $2.00) on shares of Cognition Therapeutics in a research note on Friday, November 21st. Wall Street Zen upgraded Cognition Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Brookline Capital Acquisition raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Cognition Therapeutics has a consensus rating of “Buy” and a consensus target price of $3.33.

Cognition Therapeutics Trading Up 6.0%

Shares of NASDAQ:CGTX traded up $0.06 during midday trading on Tuesday, reaching $1.06. 971,172 shares of the company were exchanged, compared to its average volume of 992,105. The stock has a market cap of $93.57 million, a PE ratio of -2.21 and a beta of 1.25. The business’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.56. Cognition Therapeutics has a one year low of $0.22 and a one year high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. As a group, sell-side analysts expect that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. increased its position in Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after acquiring an additional 7,641 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its stake in shares of Cognition Therapeutics by 69.1% during the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock worth $53,000 after purchasing an additional 16,129 shares during the period. Jones Financial Companies Lllp bought a new position in Cognition Therapeutics during the 3rd quarter valued at about $25,000. Gamco Investors INC. ET AL purchased a new stake in Cognition Therapeutics in the 3rd quarter worth about $27,000. Finally, Private Management Group Inc. purchased a new stake in Cognition Therapeutics in the 3rd quarter worth about $32,000. 43.35% of the stock is currently owned by institutional investors.

Trending Headlines about Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and released a set of quarterly and full‑year EPS estimates that are less negative than market consensus (Brookline FY2026: -$0.46 vs. consensus -$0.80). The upgrade plus narrower loss estimates likely improved investor expectations for future valuation and financing needs. Brookline coverage (MarketBeat)
• Positive Sentiment: Cognition extended the duration of its expanded access program (EAP) for Zervimesine (CT1812) in dementia with Lewy bodies, allowing enrolled patients additional months of treatment — a sign of ongoing clinical engagement and potential real‑world data generation that can de‑risk the program incrementally. GlobeNewswire: EAP extension
• Neutral Sentiment: Multiple Brookline research notes repeated the same forward‑looking quarterly estimates (Q4‑2025 through Q4‑2026) and the Strong‑Buy call — the breadth of published estimates helps set expectations but adds little new detail beyond the upgrade. Brookline coverage (MarketBeat)
• Negative Sentiment: Despite the more favorable forecasts from Brookline, Cognition remains a clinical‑stage company with no approved products and ongoing projected losses (consensus FY current year ~ -$0.80 EPS). That keeps the stock exposed to clinical, regulatory and financing risk, which can drive volatility and dilution. Market context (MarketBeat)

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.